Abiopharma

AVALO THERAPEUTICS, INC. (AVTX)

Symbol	AVTX
Name	AVALO THERAPEUTICS, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	540 GAITHER ROAD,SUITE 400, ROCKVILLE, Maryland, 20850, United States
Telephone	+1 410 522-8707
Fax	—
Email	—
Website	https://www.avalotx.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001534120
Description	Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006. Additional info from NASDAQ: Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.

2026-09-11 20:10

Sullivan Christopher Ryan 🟡 adjusted position in 10.2K shares (1 derivative) of Avalo Therapeutics, Inc. (AVTX) at $17.62 Transaction Date: Sep 10, 2026 | Filing ID: 000021

2026-09-04 20:05

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

2026-09-04 20:05

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

2026-09-03 11:00

Avalo Therapeutics to Participate in Upcoming Investor Conferences

2026-09-03 11:00

Avalo Therapeutics to Participate in Upcoming Investor Conferences

2026-09-01 20:38

Doyle Mittie 🟡 adjusted position in 679 shares (1 derivative) of Avalo Therapeutics, Inc. (AVTX) at $20.00 Transaction Date: Aug 28, 2026 | Filing ID: 000031

2026-08-19 20:10

Sullivan Christopher Ryan 🟡 adjusted position in 72.7K shares (3 derivative) of Avalo Therapeutics, Inc. (AVTX) at $20.05 ($2.9M) Transaction Date: Aug 17, 2026 | Filing ID: 000019

2026-08-19 20:10

Doyle Mittie 🟡 adjusted position in 1.0K shares (1 derivative) of Avalo Therapeutics, Inc. (AVTX) at $20.00 Transaction Date: Aug 17, 2026 | Filing ID: 000029

2026-08-18 20:18

📋 CHRISTOPHER RYAN SULLIVAN (Officer) plans to sell 31K shares of AVALO THERAPEUTICS, INC. (at $20.05 each, total $622K) Filed: Aug 18, 2026 | ID: 008317

2026-08-17 20:49

📋 MITTIE DOYLE (Officer) plans to sell 5K shares of AVALO THERAPEUTICS, INC. (at $19.59 each, total $99K) Filed: Aug 17, 2026 | ID: 008276

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT06603077	A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Modera…	Phase2	Hidradenitis Suppurativa	Completed	2024-09-16	2026-03-17	ClinicalTrials.gov
NCT05288504	A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Po…	Phase2	Non-Eosinophilic Asthma	Completed	2022-02-24	2023-05-11	ClinicalTrials.gov
NCT04994002	A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 i…	Phase1	Lymphatic Malformation	Withdrawn	2021-09-03	2022-06-01	ClinicalTrials.gov
NCT04671251	Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Mye…	Phase1	Multiple Myeloma	Completed	2020-12-15	2022-03-30	ClinicalTrials.gov
NCT03169894	Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With…	Phase1	Crohn Disease	Terminated	2017-07-14	2021-10-12	ClinicalTrials.gov
NCT02459236	A Study of Intermittent Doses of CERC-301 in MDD	Phase2	Major Depressive Disorder	Completed	2015-06-01	2016-12-01	ClinicalTrials.gov
NCT01941043	A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CE…	Phase2	Major Depressive Disorder	Completed	2013-11-01	2014-10-01	ClinicalTrials.gov
NCT01703923	An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough	Phase2	Chronic Refractory Cough	Completed	2012-11-01	2013-09-01	ClinicalTrials.gov
NCT01597349	Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respir…	Phase2	Acute Cough	Completed	2012-05-01	2012-09-01	ClinicalTrials.gov
NCT01579526	A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozeng…	Phase1	Healthy	Completed	2012-04-01	2012-05-01	ClinicalTrials.gov

Total clinical trials: 10

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
CERC-006	Other	Phase PHASE1	Lymphatic Malformation	WITHDRAWN	NCT04994002
FP01	Other	Phase PHASE1	Healthy	COMPLETED	NCT01579526
FP01	Other	Phase PHASE2	Acute Cough	COMPLETED	NCT01597349
placebo	Other	Phase PHASE2	Chronic Refractory Cough	COMPLETED	NCT01703923
FP01	Other	Phase PHASE2	Chronic Refractory Cough	COMPLETED	NCT01703923
Placebo	Other	Phase PHASE2	Major Depressive Disorder	COMPLETED	NCT02459236
CERC-301	Other	Phase PHASE2	Major Depressive Disorder	COMPLETED	NCT02459236
Placebo	Other	Phase PHASE2	Major Depressive Disorder	COMPLETED	NCT01941043
CERC-301	Other	Phase PHASE2	Major Depressive Disorder	COMPLETED	NCT01941043
MDGN-002	Other	Phase PHASE1	Crohn Disease	TERMINATED	NCT03169894
AEVI-007	Other	Phase PHASE1	Multiple Myeloma	COMPLETED	NCT04671251
Placebo	Other	Phase PHASE2	Non-Eosinophilic Asthma	COMPLETED	NCT05288504
AVTX-002	Other	Phase PHASE2	Non-Eosinophilic Asthma	COMPLETED	NCT05288504
Placebo	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 2	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 1	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
Placebo	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 2	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 1	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
Placebo	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 2	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 1	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
Placebo	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 2	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 1	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
Placebo	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 2	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 1	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
Placebo	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 2	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 1	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
Placebo	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 2	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 1	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
Placebo	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 2	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 1	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
Placebo	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 2	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 1	Other	Phase PHASE2	Hidradenitis Suppurativa	COMPLETED	NCT06603077
AVTX-009 Regimen 2	DRUG	Phase PHASE2	Hidradenitis Suppurativa	ACTIVE_NOT_RECRUITING	NCT06603077
AVTX-009 Regimen 1	DRUG	Phase PHASE2	Hidradenitis Suppurativa	ACTIVE_NOT_RECRUITING	NCT06603077
AVTX-002	DRUG	Phase PHASE2	Non-Eosinophilic Asthma	COMPLETED	NCT05288504
CERC-006	DRUG	Phase PHASE1	Lymphatic Malformation	WITHDRAWN	NCT04994002
AEVI-007	DRUG	Phase PHASE1	Multiple Myeloma	COMPLETED	NCT04671251
MDGN-002	DRUG	Phase PHASE1	Crohn Disease	TERMINATED	NCT03169894
Placebo	DRUG	Phase PHASE2	Hidradenitis Suppurativa	ACTIVE_NOT_RECRUITING	NCT06603077
CERC-301	DRUG	Phase PHASE2	Major Depressive Disorder	COMPLETED	NCT02459236
placebo	DRUG	Phase PHASE2	Chronic Refractory Cough	COMPLETED	NCT01703923
FP01	DRUG	Phase PHASE2	Chronic Refractory Cough	COMPLETED	NCT01703923

Total products: 50